Digg It
#1 in Business Subscribe Email Print

You are here: Home > Business > Management > Benchmarking and Performance Management (1)

Tags

  • drugs
  • would
  • product
  • combination products
  • companies involved

  • Links

  • Last Will and Testament Software
  • Personal Loans and APR - Is that all that Matters?
  • Forex Trading: Margin Usage and Introduction to Hedging
  • Digg It - Benchmarking and Performance Management (1)

    Comparing outcomes could be fascinating. For example if you are eager t
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    o know whether there are more divorces in Hollywood than on average?

    T
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    o measure the length of someone you can use a yard-stick, ruler or a me
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    asuring tape. If you have taken the measure, you can than compare it wi
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    h others. If you want to compare the performance of activities, or the
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    level of a competence or capability, you can use a benchmark.

    A benchm
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    ark could be the outcome of activities or competences that have previou
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    ly been measured. Such a benchmark serves like a reference, like a norm
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    that can been set as a target.

    Mutual fund managers use benchmarks to
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    set their performance target. This can be any index that is related to
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    the funds (for example the Dow Jones Industrial Index). The index is co
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    mposed of different stocks according to their weighted value in the ind
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    ex. During the year, the index will change, because of the price change
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    s of the stock values. If the fund manager invests in the same way as t
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    e index is established, the performance of the mutual fund will equal t
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    he index. By taking slightly different investment decision – resultin
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    g in a bias from the portfolio against the index – the investor will be
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    able to beat the index or benchmark.

    In the same way, an organization
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    can setup a benchmark with which the performance of the organization co
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    uld be measured. This could be done in different ways

    © 2006 Hans Boo


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.diggit.org.ua/article/23241/diggit-Benchmarking-and-Performance-Management-1.html">Benchmarking and Performance Management (1)</a>

    BB link (for phorums):
    [url=http://www.diggit.org.ua/article/23241/diggit-Benchmarking-and-Performance-Management-1.html]Benchmarking and Performance Management (1)[/url]

    Related Articles:

    Private Mailbox vs PO Box

    The 7 P's of Business Phone Etiquette

    Management in the New Information Economy; Consider it

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com